1. 10 Performance of SLEDAI-2K Responder Index-50 in a Randomized Placebo-Controlled Trial with Ustekinumab (UST) in Systemic Lupus Erythematosus. (April 2019) Authors: Touma, Zahi; Gladman, Dafna D; Fei, Kaiyin; Irene Gregan, Y; Gordon, Robert; Lo, Kim Hung; Rose, Shawn; Urowitz, Murray B Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0041 MAINTENANCE OF EFFICACY AND SAFETY AND REDUCTION OF BILAG FLARES WITH USTEKINUMAB, AN INTERLEUKIN-12/23 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): 1-YEAR RESULTS OF A PHASE 2, RANDOMIZED PLACEBO-CONTROLLED, CROSSOVER STUDY. (June 2019) Authors: Vollenhoven, Ronald van; Tsokos, George; Gordon, Robert; Lo, Kim Hung; Irene Gregan, Y; Fei, Kaiyin; Rose, Shawn; Hahn, Bevra H. Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0250 EARLY IMPROVEMENT IN SLEDAI-2K RESPONDER INDEX-50 PREDICTS SRI-4 RESPONSE IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF USTEKINUMAB (UST) IN SYSTEMIC LUPUS ERYTHEMATOSUS. (June 2019) Authors: Touma, Zahi; Gladman, Dafna D; Rose, Shawn; Fei, Kaiyin; Irene Gregan, Y; Gordon, Robert; Lo, Kim Hung; Urowitz, Murray B Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 402 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗